NASDAQ:GBTGlobal Blood Therapeutics Stock Price, Forecast & News

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GBT stock has increased by 29.0% and is now trading at $70.75. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Global Blood Therapeutics.

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Global Blood Therapeutics.

Global Blood Therapeutics Inc (NASDAQ:GBT) announced its earnings results on Wednesday, May, 6th. The company reported ($1.20) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.27. The company had revenue of $14.12 million for the quarter, compared to the consensus estimate of $3.65 million. During the same period in the prior year, the firm posted ($0.87) EPS. View Global Blood Therapeutics' earnings history.

17 Wall Street analysts have issued twelve-month target prices for Global Blood Therapeutics' shares. Their forecasts range from $60.00 to $150.00. On average, they anticipate Global Blood Therapeutics' share price to reach $105.00 in the next year. This suggests a possible upside of 48.4% from the stock's current price. View analysts' price targets for Global Blood Therapeutics.

Media coverage about GBT stock has been trending somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Global Blood Therapeutics earned a news impact score of 1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Global Blood Therapeutics.

Global Blood Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 10,160,000 shares, an increase of 6.3% from the June 15th total of 9,560,000 shares. Based on an average daily trading volume, of 873,900 shares, the short-interest ratio is presently 11.6 days. Approximately 17.1% of the shares of the stock are short sold. View Global Blood Therapeutics' Current Options Chain.

Some companies that are related to Global Blood Therapeutics include Beigene (BGNE), Merck KGaA (MKGAF), Sarepta Therapeutics (SRPT), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), ACADIA Pharmaceuticals (ACAD), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Mylan (MYL) and Perrigo (PRGO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Cynosure (CYNO), TherapeuticsMD (TXMD), Exelixis (EXEL), AbbVie (ABBV), Advanced Micro Devices (AMD), Square (SQ) and Vertex Pharmaceuticals (VRTX).

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GBT stock can currently be purchased for approximately $70.75.

Global Blood Therapeutics has a market capitalization of $4.31 billion and generates $2.11 million in revenue each year. The company earns $-266,770,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.

The official website for Global Blood Therapeutics is www.gbt.com.

Global Blood Therapeutics' mailing address is 181 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]